against mda modified apo b 100 sequences predicts short term risk for development of acute coronary events in individuals that would not have been identified as high risk by screening of established risk factors suggest that it may become a useful instrument in identifying individuals in need of aggressive preventive treatment however considerably larger prospective studies with multivariate analysis are required before the clinical value of determining antibodies against apo b 100 mda modified peptide sequences can be fully established another limitation of the present clinical study is that we have only analyzed antibodies against a small number of the antigenic sites in apo b 100 and that antibody titers against other sites may be even better markers of cardiovascular risk in subjects below age 60 antibodies against a large number of mda modified sites in apo b 100 were correlated with the extent of existing vascular disease as assessed by carotid imt igm antibodies were more closely associated with carotid imt than igg antibodies although carotid imt has obvious limitations as a measure of general atherosclerotic burden these observations still suggest that determination of igm against mda modified sequences in apo b 100 may be one method to assess the severity of existing atherosclerosis these observations are also in line with several previous studies that have reported associations between coronary and carotid artery disease and igm antibodies against oxidized ldl antibodies against peptide 74 differed against other apo b 100 peptide antibodies in many respect they were higher in controls than in cases they did not decrease with age and were not.